Company: CBLO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001882781-25-000042
Chunk: 19

Company: C2 Blockchain, Inc.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 19
---
advice and guidance, interpretation of existing and/or changing rules and principles, segregation of management duties, scale of organization,
and personnel factors. Internal control over financial reporting is a process which involves human diligence and compliance and is subject
to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented
by collusion or improper management override. Because of its inherent limitations, internal control over financial reporting may not
prevent or detect misstatements on a timely basis, however these inherent limitations are known features of the financial reporting process
and it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Therefore, even those systems determined
to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate.

Changes
in Internal Control over Financial Reporting

There
have been no changes in our internal controls over financial reporting that have occurred for the fiscal quarter ended September 30,
2025, that have materially or are reasonably likely to materially affect, our internal controls over financial reporting.

-4-

Table
of Contents

PART
II-OTHER INFORMATION

    ITEM 1
    LEGAL PROCEEDINGS

There
are no legal proceedings against the Company and the Company is unaware of such proceedings contemplated against it.

    ITEM 1A
    RISK FACTORS

As
a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for
by this Item.

    ITEM
    2
    UNREGISTERED SALES OF EQUITY SECURITIES AND USE
    OF PROCEEDS

*The following information includes all relevant transactions that occurred after the Company’s fiscal year ended June 30, 2025,
and through the quarter ended September 30, 2025.

The dates below reflect the execution dates of the subscription agreements and do not necessarily
correspond to the dates when payment was received or when the shares were actually recorded by the Company.

On or about July 15, 2025, the Company issued 5,000,000 shares of restricted common
stock at $0.02 per share for total proceeds of $100,000, and 10,000,000 shares at $0.02 per share for